Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
The future of pain management may combine genetic engineering and small-molecule drugs. Coda Biotherapeutics, a South San Francisco-based start-up, has raised $19 million in series A financing to develop treatments that use gene therapy to insert engineered ion channels into sensory neurons. The neurons are subsequently turned on or off with a small molecule that binds the channel to numb pain. The technique, part of a field called chemogenetics, is based on research by Coda cofounder and University of Pittsburgh scientist Joseph C. Glorioso III.
This article has been sent to the following recipient: